RA Capital Management Directors Awarded Equity in Acumen Pharmaceuticals

RA Capital Management, L.P. and related entities filed a Form 4 reporting equity awards to Laura Stoppel, a Principal of the Adviser who serves on Acumen Pharmaceuticals' board of directors. On June 3, 2026, Stoppel received 35,500 restricted stock units (RSUs) and 53,250 stock options with a $2.29 exercise price, both vesting on the earlier of the first anniversary or the 2027 annual stockholder meeting. The filing discloses that RA Capital Management, RA Capital Healthcare Fund LP, and RA Capital Nexus Fund II, L.P. collectively hold over 20.9 million shares of Acumen Pharmaceuticals common stock. The awards are structured such that Stoppel holds them for the benefit of RA Capital's funds and accounts, with any proceeds offsetting advisory fees owed by those entities.